| Literature DB >> 31110543 |
Li Jiang1, Li Hong1, Wenwu Yang1, Yuzi Zhao1, Aili Tan1, Yang Li1.
Abstract
INTRODUCTION: Cervical cancer is the second most common type of cancer and the third leading cause of cancer deaths in females in developing countries. Recent studies showed that long non-coding RNAs play a key role in human cancers. However, the molecular mechanisms underlying the initiation and progression of cervical cancer remained to be further explored.Entities:
Keywords: cervical cancer; expression profiling; long non-coding RNAs; protein-protein interaction analysis
Year: 2019 PMID: 31110543 PMCID: PMC6524193 DOI: 10.5114/aoms.2019.84740
Source DB: PubMed Journal: Arch Med Sci ISSN: 1734-1922 Impact factor: 3.318
The top 10 up-regulated mRNAs in cervical cancer progression
| Gene name | Ave (normal) | Ave (CIN1) | Ave (CIN2) | Ave (CIN3) | Ave (tumor) | FC (CIN1 vs. normal) | FC (CIN2 vs. normal) | FC (CIN3 vs. normal) | FC (tumor vs. normal) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NUP210 | 2.97 | 4.34 | 4.59 | 7.33 | 7.44 | 2.58 | 3.06 | 20.51 | 22.22 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| MMP12 | 3.83 | 5.28 | 5.70 | 7.25 | 8.88 | 2.73 | 3.65 | 10.65 | 33.06 | 0.10 | 0.02 | < 0.001 | < 0.001 |
| SYNGR3 | 3.50 | 5.36 | 5.67 | 8.20 | 7.51 | 3.62 | 4.49 | 25.95 | 16.04 | 0.01 | < 0.001 | < 0.001 | < 0.001 |
| HS6ST2 | 4.23 | 6.63 | 6.88 | 8.58 | 8.61 | 5.30 | 6.29 | 20.45 | 20.86 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| HS6ST2 | 5.93 | 8.61 | 8.58 | 10.49 | 10.02 | 6.43 | 6.31 | 23.65 | 17.02 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| ZIC2 | 2.79 | 3.22 | 4.20 | 5.82 | 8.31 | 1.35 | 2.66 | 8.19 | 46.13 | 0.12 | 0.02 | < 0.001 | < 0.001 |
| CTHRC1 | 5.95 | 6.34 | 7.60 | 9.07 | 11.68 | 1.31 | 3.14 | 8.73 | 53.10 | 0.69 | 0.05 | < 0.001 | < 0.001 |
| ELAVL2 | 2.31 | 4.32 | 5.32 | 6.82 | 7.69 | 4.02 | 8.06 | 22.73 | 41.52 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| SYCP2 | 4.11 | 5.56 | 7.57 | 9.23 | 9.26 | 2.72 | 11.02 | 34.73 | 35.41 | 0.05 | < 0.001 | < 0.001 | < 0.001 |
| CDKN2A | 4.07 | 6.90 | 9.37 | 10.67 | 10.47 | 7.15 | 39.46 | 96.88 | 84.76 | 0.02 | < 0.001 | < 0.001 | < 0.001 |
The top 10 down-regulated mRNAs in cervical cancer progression
| Gene name | Ave (normal) | Ave (CIN1) | Ave (CIN2) | Ave (CIN3) | Ave (tumor) | FC (CIN1 vs. normal) | FC (CIN2 vs. normal) | FC (CIN3 vs. normal) | FC (tumor vs. normal) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRISP3 | 13.32 | 9.88 | 10.49 | 7.67 | 4.41 | 0.09 | 0.14 | 0.02 | 0.00 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| CRISP2 | 8.02 | 4.72 | 5.37 | 3.59 | 2.91 | 0.10 | 0.16 | 0.05 | 0.03 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| RPTN | 8.05 | 5.01 | 5.96 | 4.33 | 3.45 | 0.12 | 0.24 | 0.08 | 0.04 | 0.02 | 0.06 | < 0.001 | < 0.001 |
| UPK1A | 8.11 | 6.41 | 5.78 | 3.88 | 2.43 | 0.31 | 0.20 | 0.05 | 0.02 | 0.22 | 0.05 | < 0.001 | < 0.001 |
| ZBED2 | 8.14 | 6.60 | 5.60 | 4.44 | 3.53 | 0.34 | 0.17 | 0.08 | 0.04 | 0.15 | 0.01 | < 0.001 | < 0.001 |
| LCE3D | 10.36 | 8.04 | 8.73 | 7.30 | 5.00 | 0.20 | 0.32 | 0.12 | 0.02 | 0.13 | 0.22 | 0.01 | < 0.001 |
| CRCT1 | 8.67 | 7.13 | 6.64 | 5.25 | 3.33 | 0.34 | 0.25 | 0.09 | 0.02 | 0.30 | 0.12 | < 0.001 | < 0.001 |
| KRT2 | 5.37 | 3.80 | 2.85 | 3.08 | 1.83 | 0.34 | 0.17 | 0.20 | 0.09 | 0.22 | 0.02 | 0.01 | < 0.001 |
| EPB41L3 | 8.22 | 6.83 | 5.58 | 5.20 | 5.79 | 0.38 | 0.16 | 0.12 | 0.19 | 0.09 | < 0.001 | < 0.001 | < 0.001 |
| GYS2 | 6.09 | 4.65 | 4.29 | 3.17 | 2.35 | 0.37 | 0.29 | 0.13 | 0.07 | 0.21 | 0.07 | < 0.001 | < 0.001 |
Figure 1Identification of differentially expressed mRNAs and lncRNAs in cervical cancer. A – Hierarchical clustering analysis shows differential mRNAs expression in cervical cancer by using GSE63514. B – Hierarchical clustering analysis shows differential lncRNAs expression in cervical cancer by using GSE63514
The top 10 up-regulated lncRNAs in cervical cancer progression
| Gene name | Ave (normal) | Ave (CIN1) | Ave (CIN2) | Ave (CIN3) | Ave (tumor) | FC (CIN1 vs. normal) | FC (CIN2 vs. normal) | FC (CIN3 vs. normal) | FC (tumor vs. normal) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RP11-1L12.3 | 2.78 | 3.90 | 4.28 | 5.58 | 5.23 | 2.16 | 2.82 | 6.96 | 5.46 | 0.07 | 0.02 | < 0.001 | < 0.001 |
| LINC01305 | 2.59 | 3.24 | 4.01 | 5.41 | 5.46 | 1.57 | 2.67 | 7.06 | 7.31 | 0.09 | 0.03 | < 0.001 | < 0.001 |
| LOC375196 | 2.87 | 3.44 | 4.47 | 6.16 | 5.69 | 1.49 | 3.04 | 9.83 | 7.08 | 0.19 | < 0.001 | < 0.001 | < 0.001 |
| ANKRD36BP2 | 5.03 | 7.32 | 6.26 | 7.00 | 8.65 | 4.90 | 2.35 | 3.93 | 12.34 | 0.01 | 0.07 | 0.01 | < 0.001 |
| LINC00925 | 3.07 | 3.72 | 4.91 | 7.00 | 5.82 | 1.57 | 3.57 | 15.19 | 6.71 | 0.16 | < 0.001 | < 0.001 | < 0.001 |
| CTA-384D8.35 | 2.59 | 4.04 | 3.93 | 6.29 | 6.50 | 2.73 | 2.52 | 12.96 | 14.96 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| ABCA17P | 2.92 | 4.58 | 5.28 | 7.56 | 6.72 | 3.17 | 5.15 | 24.98 | 13.97 | 0.01 | < 0.001 | < 0.001 | < 0.001 |
| TCAM1P | 3.30 | 4.71 | 6.62 | 8.09 | 7.94 | 2.66 | 9.97 | 27.68 | 24.85 | 0.01 | < 0.001 | < 0.001 | < 0.001 |
| RP1-93H18.6 | 4.64 | 5.97 | 5.64 | 6.94 | 6.97 | 2.51 | 2.01 | 4.94 | 5.04 | 0.01 | 0.02 | < 0.001 | < 0.001 |
| AC128677.4 | 2.78 | 3.43 | 3.61 | 4.83 | 5.54 | 1.57 | 1.77 | 4.15 | 6.77 | 0.22 | 0.12 | < 0.001 | < 0.001 |
The top 10 down-regulated lncRNAs in cervical cancer progression
| Gene name | Ave (normal) | Ave (CIN1) | Ave (CIN2) | Ave (CIN3) | Ave (tumor) | FC (CIN1 vs. normal) | FC (CIN2 vs. normal) | FC (CIN3 vs. normal) | FC (tumor vs. normal) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYP2B7P | 7.43 | 6.38 | 5.77 | 5.19 | 4.23 | 0.48 | 0.32 | 0.21 | 0.11 | 0.30 | 0.06 | < 0.001 | < 0.001 |
| PRSS3P2 | 7.03 | 5.98 | 5.85 | 4.25 | 4.01 | 0.48 | 0.44 | 0.15 | 0.12 | 0.03 | < 0.001 | < 0.001 | < 0.001 |
| RAB11B-AS1 | 7.15 | 6.14 | 6.03 | 4.75 | 3.99 | 0.50 | 0.46 | 0.19 | 0.11 | 0.07 | 0.02 | < 0.001 | < 0.001 |
| LINC01214 | 4.51 | 3.38 | 3.15 | 2.65 | 2.44 | 0.46 | 0.39 | 0.28 | 0.24 | 0.16 | 0.02 | < 0.001 | < 0.001 |
| RP11-774O3.3 | 5.60 | 4.84 | 4.43 | 3.16 | 3.06 | 0.59 | 0.44 | 0.18 | 0.17 | 0.17 | 0.02 | < 0.001 | < 0.001 |
| HCG22 | 5.20 | 3.73 | 4.31 | 3.40 | 3.15 | 0.36 | 0.54 | 0.29 | 0.24 | 0.05 | 0.17 | < 0.001 | < 0.001 |
| ZNF300P1 | 7.06 | 6.53 | 5.79 | 4.90 | 3.90 | 0.69 | 0.41 | 0.22 | 0.11 | 0.47 | 0.03 | < 0.001 | < 0.001 |
| FLG-AS1 | 7.34 | 6.64 | 6.48 | 4.81 | 4.00 | 0.62 | 0.55 | 0.17 | 0.10 | 0.33 | 0.20 | < 0.001 | < 0.001 |
| LOC100507487 | 6.58 | 6.24 | 5.39 | 3.62 | 3.50 | 0.79 | 0.44 | 0.13 | 0.12 | 0.62 | 0.02 | < 0.001 | < 0.001 |
| LINC01094 | 5.37 | 4.78 | 4.13 | 3.55 | 3.60 | 0.66 | 0.42 | 0.28 | 0.29 | 0.48 | 0.07 | < 0.001 | < 0.001 |
Figure 2Construction of PPI networks for differentially expressed mRNAs in cervical cancer. The top 5 up-regulated hub-networks and top 3 down-regulated hub-networks
Figure 3Co-expression network analysis of differentially expressed lncRNAs in cervical cancer progression. The gene co-expression network between lncRNAs and mRNAs in cervical cancer progression. 278 lncRNAs and 786 mRNAs were included in this network
Figure 4GO and KEGG analysis of differentially expressed lncRNAs in cervical cancer progression. A–C – GO analysis shows differentially expressed lncRNA associated biological processes (A), cellular component (B) and molecular function (C). D – KEGG pathway analysis shows differentially expressed lncRNAs associated pathways
Figure 5Functional prediction of key lncRNA-mRNAs network. A – Hub lncRNA-mRNAs network 1 was involved in regulating Th1 and Th2 cell differentiation, Wnt signaling pathway, glycosaminoglycan biosynthesis and protein O-linked glycosylation. B – Hub lncRNA-mRNAs network 2 was involved in regulating cell cycle, cellular response to DNA damage stimulus, chromosome organization, and immune response